TrialReader


Comparison of the Non-invasive Biobeat Device With an Invasive Arterial Line

NCT03603860 — Completed, 18 participants, Biobeat Technologies Ltd.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Comparison of Continuous Blood Pressure Measurement Using the Non-invasive, Wireless Biobeat Monitor With an Invasive Arterial Line

RegistryNCT03603860
StatusCompleted
Study typeObservational
Enrollment18 (Actual)
SponsorBiobeat Technologies Ltd. (Industry); collaborators: The Baruch Padeh Medical Center, Poriya
ConditionsBlood Pressure, Heart Diseases
InterventionsNon-invasive monitoring (Device)
Datesstart 2018-11-05, primary completion 2020-02-05, completion 2020-03-05, first posted 2018-07-27, last updated 2020-07-09
Locations1 site in Israel

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Blood Pressure All trials for Heart Diseases All trials of Non-invasive monitoring

-Summary

In this clinical study the investigators will compare blood pressure measurements obtained using the non-invasive, continuous and wireless Biobeat monitoring device (a wrist watch or a patch configuration) to an invasive arterial line (radial or femoral) in 30 patients immediately after cardiac surgery, at the intensive care unit.

Expand all sections  ·  Collapse all

+Detailed description

The Biobeat non-invasive, continuous and wireless monitoring device is based on photoplethysmograph technology. It measures several vital signs, including blood pressure, stroke volume, pulse rate, pulse pressure, heart rate variability, respiratory rate, saturation, cardiac output, cardiac index, and more. The data is transmitted to Biobeat's application (in both Apple and Google Play), and is available on the individual's cellular phone, tablet, or as a full monitoring system in a hospital department. The aim of this study is to compare the Biobeat monitor with the invasive method of blood pressure measurement, an arterial line. The study population includes 30 patients undergoing cardiac surgery. As per local protocol, each one of the participants will come out from the operating room with an arterial line. Once in the intensive care unit, the investigators will attach the Biobeat non-invasive monitor (either wrist watch or a patch, these two configurations are identical in terms of the monitoring system), and monitor the participants for 4 hours. Though both methods are continuous, the investigators will record the vital signs every 15 minutes during the 4 hours of the study.

+Arms and interventions

  • Non-invasive monitoring (Device): Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line

+Outcome measures

Primary outcomes

  • Level of accordance between the Biobeat monitor and the arterial line [4 hours per individual]: Comparing blood pressure measurements of the Biobeat device with those of the arterial line. Both systolic blood pressure and diastolic blood pressure will be assessed during the study period.

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients arriving immediately after cardiac surgery to the intensive care unit with an arterial line.

Exclusion Criteria:

* Refusal to participate
* Patients with no arterial line
* Pregnant women
* Individuals under the age of 18 years
* Patients with lack of judgment/mental illness
* Patients working in the Baruch Padeh Medical Center

+Locations (1)

FacilityCityCountryStatus
The Baruch Padeh Medical Center, PoriyaTiberias, Lower GalileeIsrael

+Publications

  • Results publication: Eisenkraft A, Goldstein N, Ben Ishay A, Fons M, Tabi M, Sherman AD, Merin R, Nachman D. Clinical validation of a wearable respiratory rate device: A brief report. Chron Respir Dis. 2023 Jan-Dec;20:14799731231198865. doi: 10.1177/14799731231198865. PMID 37612250
  • Results publication: Kachel E, Constantini K, Nachman D, Carasso S, Littman R, Eisenkraft A, Gepner Y. A Pilot Study of Blood Pressure Monitoring After Cardiac Surgery Using a Wearable, Non-invasive Sensor. Front Med (Lausanne). 2021 Aug 5;8:693926. doi: 10.3389/fmed.2021.693926. eCollection 2021. PMID 34422859

+Investigators

  • Erez Kachel, MD, Principal investigator, The Baruch Padeh Medical Center, Poriya, Israel

My Notes